[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adpkd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adpkd":14},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,37,67,91,115,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100388454","autosomal-dominant-polycystic-kidney-disease-adpkd-study-100388454",false,"NCT04338048","Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study","ADPKD","Inclusion Criteria:\n\n* Demonstration of ADPKD by clinical information, imaging studies, biopsy, autopsy, or genetic testing.\n\nExclusion Criteria:\n\n* Patients with Autosomal Recessive Polycystic Kidney disease (ARPKD), urinary tract malformations or major congenital anomalies of other systems suggesting a diagnosis other than recessive hepato-renal fibrocystic diseases.","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of renal failure. For several decades, ADPKD was regarded as an adult-onset disease. In the last decade, it has become more widely appreciated that the disease course begins in childhood. However, evidence-based guidelines on how to manage and approach children diagnosed with or at-risk for of ADPKD are lacking. Overall, there is insufficient data on the clinical course during childhood. The study intends to get more information on Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other hepato\u002Frenal fibrocystic diseases. Additionally, the study intends to expand web-based resources so anyone can learn about ADPKD or other hepato\u002Frenal fibrocystic diseases. Individuals diagnosed with the dominant form of a hepato\u002Frenal fibrocystic condition are invited to be in the study.",[14],"RECRUITING","2026-06-12",{"date":27,"type":28},"2026-06-15","ACTUAL",{"date":30,"type":28},"2019-10-10",{"date":32,"type":20},"2030-10-30",{"name":34,"class":35},"Children's Hospital of Philadelphia","OTHER",4,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":44,"enrollmentInfo":45,"targetDuration":4,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":51,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100467937","phase-3-hydrochlorothiazide-to-protect-polycystic-kidney-disease-patients-and-improve-their-quality-of-life-100467937","NCT05373264","HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life","HYDRO-PROTECT","Inclusion Criteria:\n\n* ADPKD diagnosis (modified Ravine criteria)\n* ≥18 years old\n* eGFR \\> 25 mL\u002Fmin\u002F1.73m2\n* On stable treatment with the highest tolerated dose of V2RA for a minimum of 3 months\n\nExclusion Criteria:\n\n* Known intolerance to hydrochlorothiazide\n* Use of any diuretic\n* Orthostatic hypotension complaints or blood pressure \\\u003C105\u002F65mmHg during screening visit\n* Uncontrolled hypertension (blood pressure \\>160\u002F100mmHg)\n* Hypokalemia (\\\u003C3.5 mmol\u002FL)\n* History of active gout on maintenance preventive treatment for gout (allopurinol, desuric and\u002For colchicine), defined as ≥2 episodes during the last year\n* History of skin cancer (basal cell, squamous cell and melanoma)","80 Years",{"count":19,"type":20},"INTERVENTIONAL",[48],"PHASE3","Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive formation of renal cysts which ultimately lead to a loss of renal function.\n\nTolvaptan (a V2R antagonist) is currently the only effective treatment for preserving renal function in ADPKD. However, side-effects such as polyuria limit its tolerability and thereby the therapeutic potential. This study will test whether co-administration with hydochlorothiazide can improve V2RA efficacy (slowing kidney function decline) and tolerability (quality of life) in ADPKD. Approximately 300 patients will be enrolled.",[14],[14,52,53,54,55,56],"Tolvaptan","Hydrochlorothiazide","Quality of Life","Side effects","Polyuria","2026-02-23",{"date":59,"type":28},"2026-02-25",{"date":61,"type":28},"2024-07-31",{"date":63,"type":20},"2031-07",{"name":65,"class":35},"University Medical Center Groningen",12,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100590639","somatosensory-phenotyping-of-adpkd-100590639","NCT06970028","Somatosensory Phenotyping of ADPKD","Somatosensory Phenotyping of Patients With ADPKD Using Quantitative Sensory Testing and Questionnaires","Inclusion Criteria:\n\nPatients with ADPKD\n\n* Subject is ≥ 12 years old.\n* Subject is diagnosed with ADPKD.\n\nHealthy volunteers\n\n* Subject is ≥ 12 years old.\n* Subject is in good general health, based on medical history and vital signs.\n* Subject is matched to the patient group for age, sex and BMI.\n\nExclusion Criteria:\n\nPatients with ADPKD\n\n* Subject has eczema, scleroderma, psoriasis, dermatitis, or any other abnormality on the skin of the dominant hand and\u002For lower back which, in the investigator's opinion, might interfere with the study assessments.\n* Subject is currently undergoing dialysis, had a kidney transplant or is a user of tolvaptan.\n* Female who is pregnant or breastfeeding.\n* Simultaneous participation in another study which, in the investigator's opinion, might confound the results of the study.\n* Subject is unable to refrain from drinking alcohol 24 hours prior to each study visit, and\u002For consumes ≥ 3 alcoholic consumptions per day.\n* Subject is a regular user of cannabis, any illicit drugs and\u002For has a history of drug abuse.\n* Subject is unable to refrain from drinking caffeinated beverages (such as coffee, tea, cola,…) 24 hours prior to each study visit.\n* Subject has used concomitant drugs and\u002For treatments in a period smaller than or equal to 5 half-lives prior to enrollment, that may interfere, in the investigator's opinion, with the study results.\n* Subject has a history of any illness or condition which, in the investigator's opinion, may interfere with safe and optimal participation in the study.\n\nHealthy volunteers\n\n* Subject has a history of any illness or condition which may affect the normal somatosensory functionality.\n* Subject has eczema, scleroderma, psoriasis, dermatitis, or any other abnormality on the skin of the dominant hand and\u002For lower back which, in the investigator's opinion, might interfere with the study assessments.\n* Female who is pregnant or breast-feeding.\n* Simultaneous participation in another study which, in the investigator's opinion, might confound the results of the study.\n* Subject is unable to refrain from drinking alcohol 24 hours prior to each study visit, and\u002For consumes ≥ 3 alcoholic consumptions per day.\n* Subject is a regular user of cannabis, any illicit drugs and\u002For has a history of drug abuse.\n* Subject is unable to refrain from drinking caffeinated beverages (such as coffee, tea, cola,…) 24 hours prior to each study visit.\n* Subject has used concomitant drugs and\u002For treatments in a period smaller than or equal to 5 half-lives prior to enrollment, that may interfere, in the investigator's opinion, with the study results.\n* Subject has a history of any illness or condition which, in the investigator's opinion, may interfere with safe and optimal participation in the study.",true,"12 Years",{"count":77,"type":20},150,"Over 60% of patients with ADPKD suffer from pain, mostly in the abdomen, flank and back, often leading to the diagnosis. It is challenging to manage and cure the pain; approximately 39% of patients are not satisfied with their pain treatment, since the pain prevents them from doing various activities, affecting their quality of life. Pain can be present before enlargement of the kidneys, the source of the pain is often unknown and common analgesics are insufficient to manage the pain or cannot be taken due to renal impairment. By further investigating and characterizing the pain phenotype of the ADPKD population, pain management might be improved and alternative therapeutic approaches might be developed. In this clinical study, pain will be assessed in patients with ADPKD using Quantitative Sensory Testing (QST) on the dominant hand and the lower back, together with four questionnaires regarding pain and quality of life. These results will be compared with the somatosensory profile of matched healthy volunteers.",[14,80],"Pain","2025-11-14",{"date":83,"type":28},"2025-11-17",{"date":85,"type":28},"2025-09-09",{"date":87,"type":20},"2026-12",{"name":89,"class":35},"Universitaire Ziekenhuizen KU Leuven",1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":74,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":90},"100440352","kidney-sodium-functional-imaging-100440352","NCT05014178","Kidney Sodium Functional Imaging","Kidney Sodium Functional Imaging: Evaluation of Kidney Medullary Sodium Content Using 23Na MRI in Kidney Disease","Inclusion Criteria:\n\n* Age ≥ 18 years\n* For healthy controls: lack of kidney disease, heart failure, liver cirrhosis and peripheral edema\n* For CKD stage 1-5: Estimated GFR \\\u003C 90 mL\u002Fmin\u002F1.73m²\n* For patients on maintenance hemodialysis or peritoneal dialysis: more than 3 months duration of therapy\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding or intending pregnancy\n* Contraindication to MRI\n\n  * Inability to tolerate MRI due to patient size and\u002For known history of claustrophobia.\n  * Mechanically implanted, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, tattoos, shunt, surgical staples (including clips or metallic sutures and\u002For ear implants.)",{"count":99,"type":20},200,"The corticomedullary gradient is largely responsible for developing the gradients that are needed to concentrate urine (more solutes and less water). The ability of the kidneys to produce concentrated urine is a major determinant of the ability to survive the warm weather. When temperatures are high, we lose water through sweat, and so the kidneys retain water to maintain fluidity in the blood. The maintenance of a sodium (salt) gradient is required for urine concentration because increased medullary sodium concentration increases the reabsorption of water into the kidney, to be redistributed in the blood. The purpose of this study is to know if the corticomedullary gradient is altered in patients across a wide spectrum of kidney disease using sodium Magnetic Resonance Imaging (MRI), a machine that takes pictures and measures the salt content in the kidneys. 23Na kidney MRI, will provide functional MR of the kidney as a non-invasive tool to describe medullary function to improve management of chronic and kidney disease.",[102,103,14],"Chronic Kidney Disease","Nephrolithiasis",[105],"cortico-medullary gradient","2025-02-10",{"date":108,"type":28},"2025-02-12",{"date":110,"type":28},"2021-09-16",{"date":112,"type":20},"2026-02-28",{"name":114,"class":35},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":90},"100574427","analysis-of-patients-with-autosomal-dominant-polycystic-kidney-100574427","NCT06759142","Analysis of Patients With Autosomal Dominant Polycystic Kidney","Inclusion Criteria:\n\n* Age-matched subjects with a diagnosis of ADPKD defined on the basis of the Unified Criteria of Pei. Diagnosis in subjects with a positive family history is based on age-differentiated ultrasound criteria. The presence of a \"total of 3 or more cysts\" in subjects aged 18-39 years and \"2 or more cysts in each kidney\" in at-risk subjects aged 40-59 years are sufficient to make the diagnosis of ADPKD.In the absence of family history, the presence of more than 10 cysts per kidney on ultrasound is typically considered diagnostic. Where the picture appears unclear, and particularly where the diagnosis has a major fallout (related to family planning, renal donation, initiation of specific drug treatment), genetic confirmation is strongly recommended.\n* Obtaining Informed Written Consent.\n\nExclusion Criteria:\n\n* None.",{"count":122,"type":20},180,"The main objective of the study is to establish a database of clinical data and genetic data of patients diagnosed with ADPKD, with particular focus on those who have undertaken a specific therapy (Tolvaptan or Octreotide), afferent to the Integrated Renal Genetic Diseases Outpatient Clinic of the U.O. Nephrology, Dialysis and Transplantation of the Sant'Orsola-Malpighi Polyclinic directed by Prof. La Manna. In-depth analysis and comparison on clinical, laboratory and instrumental outcomes will be performed within this population.\n\nA thorough personal and family history will be obtained, and once informed consent is obtained, data will be entered and updated during subsequent outpatient monitoring.\n\nAttention is paid to the clinical course of the disease in relation to genetic variants (genotype-phenotype correlation) and treatments performed by patients, in order to monitor the progression of the disease to end-stage renal failure (ESRD) and the impact that specific therapy has on various parameters identified as indicating such progression. In particular, monitoring of the reduction in renal function, as assessed by creatinine, eGFR, 24-hour proteinuria, and urinary osmolarity values, with attention to comparing developmental trends toward ESDR between patients not receiving therapy and patients on specific therapy, and monitoring of the numerical and\u002For volumetric increase in renal cysts, as assessed by imaging comparison of the TKV value at the time of diagnosis of polycystic kidney disease and at subsequent re-evaluation, with attention to the extent of progression following the initiation of specific therapy, will be performed.",[125,14],"Autosomal Dominant Polycystic Kidney",[14],"2024-12-30",{"date":129,"type":28},"2025-01-06",{"date":131,"type":28},"2021-02-20",{"date":133,"type":20},"2025-06-01",{"name":135,"class":35},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":145,"conditions":146,"keywords":154,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":90},"100548112","genetics-in-the-progression-of-nephropathies-100548112","NCT06416761","Genetics in the Progression of Nephropathies","The Genetic Contribution to Progression of Kidney Disease","Inclusion Criteria:\n\n. presence of specific renal disease\n\nExclusion Criteria:\n\n* to be evaluated in the different sub-protocols",{"count":144,"type":20},10000,"This study evaluates the role of genetic in the development and progression of different nephropaties with particular attention to:\n\n* AKI\n* CKD\n* Hypertension\n* ADPKD\n* CKD-MBD\n* Patients with decompensated heart failure undergoing either medical or surgery therapy\n* Patients with hematologic cancer exposed to chemotherapeutic agents or undergoing allogeneic bone marrow transplantation\n* glomerular diseases",[147,148,149,150,14,151,152,153],"AKI","CKD","Ckd-Mbd","CKD (Chronic Kidney Disease) Stage 5D","Hypertension","Hematologic Malignancy","Bone Marrow Transplant Complications",[155,156,157,158,159,160],"genetic in hypertensive kidney disease","salt intake in BP control and CKD progression","genetic in CKD","endogenous Ouabain as marker of AKI","protein intake restriction in CKD progression","hypertension in allogenic bone marrow transplantation","2024-05-11",{"date":163,"type":28},"2024-05-16",{"date":165,"type":28},"2006-05-19",{"date":167,"type":20},"2041-05-19",{"name":169,"class":35},"Ospedale San Raffaele"]